← All trials
NCT05301517
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2022
- Primary completion
- Apr 14, 2023
- Completion date
- May 12, 2023
- First posted
- Mar 29, 2022
- Last posted
- Jun 3, 2022
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- FibroGenLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.